Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 21, Issue 1, Pages 76-82Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtha.2022.10.020
Keywords
anticoagulant; cancer; catheter; coagulation; thrombosis
Categories
Ask authors/readers for more resources
This study compared the effects of apixaban, rivaroxaban, and enoxaparin on the prevention of catheter-induced clotting in vitro. The results showed that apixaban and rivaroxaban were significantly less potent than enoxaparin in preventing catheter-induced clotting and thrombin generation. Clinical trials are needed to compare the efficacy of low-molecular-weight heparin with that of direct oral anticoagulants for both prevention and treatment of catheter thrombosis.
Background: Central venous catheters are prone to clotting, particularly in patients with cancer. Although low-molecular-weight heparin and direct oral anticoagulants, such as apixaban and rivaroxaban, have been evaluated for the prevention of catheter thrombosis, their efficacy remains uncertain.Objectives: Compare apixaban and rivaroxaban with enoxaparin for the prevention of catheter-induced clotting in vitro.Methods: To address this uncertainty, we used a well-established microplate-based assay to compare the effects of enoxaparin, apixaban, and rivaroxaban on catheter -induced thrombosis and thrombin generation in human plasma. Results: Consistent with our previous findings, catheter segments shortened the clot-ting time and promoted thrombin generation. When compared at concentrations with similar anti-factor Xa activity as enoxaparin, apixaban and rivaroxaban were >20-fold less potent than enoxaparin for the prevention of catheter-induced clotting and thrombin generation.Conclusion: The prevention of catheter thrombosis in patients with cancer is chal-lenging. Clinical trials are needed to compare the efficacy of low-molecular-weight heparin with that of direct oral anticoagulants both for the prevention and treatment of catheter thrombosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available